BMC Cancer · 2008 · 60 citations · 33 references
MedicineGeneticsOncologyBreast OncologyCancer GeneticsMolecular OncologyBreast Cancer Risk AssessmentCancer GenomicsCarcinogen MetabolismGenetic Risk AssessmentCyp2c19 GenotypeEnzyme Polymorphism EffectsGenetic Prognostic MarkersGenetic Risk MarkersMetabolic Pathway PolymorphismsMetabolic PolymorphismsMetabolism Enzyme PolymorphismsRestriction Enzyme Digestion
BACKGROUND: Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. This study investigated the susceptibility and prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms in breast carcinoma patients. METHODS: The authors used polymerase chain reaction and restriction enzyme digestion to characterize the variation of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene in a total of 560 unrelated subjects (246 controls and 314 patients). RESULTS: The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively). For NAT2 the association was more pronounced among postmenopausal patients (p = 0.006). A significant association was found between CYP2D6 (G/G) wild type and breast carcinoma risk only in postmenopausal patients (p = 0.04). Association studies of genetic markers with the rates of breast carcinoma specific overall survival (OVS) and the disease-free survival (DFS) revealed among all breast carcinoma patients no association to DFS but significant differences in OVS only with the mEH gene polymorphisms (p = 0.02). In addition, the mEH wild genotype showed a significant association with decreased OVS in patients with axillary lymph node-negative patients (p = 0.03) and with decreased DFS in patients with axillary lymph node-positive patients (p = 0.001). However, the NAT2 intermediate acetylator genotype was associated with decreased DFS in axillary lymph node-negative patients. CONCLUSION: The present study may prove that polymorphisms of some XME genes may predict the onset of breast carcinoma as well as survival after treatment.
33
Estimates of the cancer incidence and mortality in Europe in 2006
Jacques Ferlay, Philippe Autier, Mathieu Boniol et al. · Annals of Oncology · 2007 · 4K citations · Full text
Ahmedin Jemal, Anish Thomas, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2002 · 2.9K citations · Full text
Medicine, Demography, Oncology +17
Henrik Zetterquist · Tissue Antigens · 1992 · 1.8K citations
Life Sciences, Genetics, Immunology +17
Estimates of cancer incidence and mortality in Europe in 1995
Freddie Bray, Risto Sankila, Jacques Ferlay et al. · European Journal of Cancer · 2002 · 688 citations